HC Wainwright & Co. Downgrades Entrada Therapeutics to Neutral

Benzinga Newsdesk May 8, 2026 5 months ago

NewsDowngradesAnalyst Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Entrada Therapeutics (NASDAQ:TRDA) from Buy to Neutral.